Table 2 Post-COVID-19 neuropsychiatric manifestations in migraine patients and controls

Post COVID-19 neuropsychiatric manifestations [n (%)]

Fatigue

64 (31.4%)

44 (21.6%)

0.025*

1.662

1.064

2.596

Neuropathic pain

35 (17.2%)

23 (11.3%)

0.089

1.63

0.925

2.871

Anosmia/hyposmia

39 (19.1%)

21 (10.3%)

0.012*

2.06

1.164

3.645

Cacosmia

20 (9.8%)

8 (3.9%)

0.019*

2.663

1.145

6.195

Ageusia/hypogeusia

30 (14.7%)

23 (11.3%)

0.303

1.357

0.758

2.427

Dizziness

34 (16.7%)

25 (12.3%)

0.205

1.432

0.82

2.5

Tinnitus

15 (7.4%)

20 (9.8%)

0.377

0.73

0.363

1.47

Cognitive dysfunction

21 (10.3%)

20 (9.8%)

0.869

1.056

0.554

2.014

Depression

42 (20.6%)

21 (10.3%)

0.004*

2.259

1.284

3.975

Anxiety

42 (20.6%)

15 (7.4%)

 ≤ 0.001*

3.267

1.747

6.108

Insomnia

48 (23.5%)

25 (12.3%)

0.003*

2.203

1.298

3.739

Headache

36 (17.6%)

13 (6.4%)

 ≤ 0.001*

3.148

1.616

6.136